What is Beam Therapeutics Debt-to-Equity?
Beam Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $12.8 Mil. Beam Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $159.9 Mil. Beam Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $981.3 Mil.
Beam Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.18.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Beam Therapeutics's Debt-to-Equity or its related term are showing as below:
BEAM'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.17 Med: 0.24 Max: 0.41
Current: 0.18
During the past 7 years, the highest Debt-to-Equity Ratio of Beam Therapeutics was 0.41. The lowest was 0.17. And the median was 0.24.
Beam Therapeutics Debt-to-Equity Historical Data
The historical data trend for Beam Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beam Therapeutics Debt-to-Equity Chart
|
Beam Therapeutics Annual Data
|
|
Trend |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
0.25 |
0.41 |
0.17 |
0.24 |
0.18 |
|
Beam Therapeutics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.24 |
0.23 |
0.22 |
0.22 |
0.18 |
Competitive Comparison of Beam Therapeutics's Debt-to-Equity
For the Biotechnology subindustry, Beam Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beam Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beam Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Beam Therapeutics's Debt-to-Equity falls into.
Beam Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Beam Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Beam Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beam Therapeutics (Beam Therapeutics) Business Description
Traded in Other Exchanges
Address
238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.
Executives
| Christine Bellon |
officer: Chief Legal Officer |
BEAM THERAPEUTICS, INC., 238 MAIN STREET, 9TH FL., CAMBRIDGE MA 02142 |
| Amy Simon |
officer: Chief Medical Officer |
BEAM THERAPEUTICS, INC., 238 MAIN STREET, 9TH FL., CAMBRIDGE MA 02142 |
| Giuseppe Ciaramella |
officer: President & CSO |
C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
| John M. Evans |
director, officer: CEO |
C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
| Terry-ann Burrell |
officer: CFO |
C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
| Fmr Llc |
10 percent owner, other: See Remark 1 |
245 SUMMER STREET, BOSTON MA 02210 |
| John Maraganore |
director |
75 SIDNEY ST, CAMBRIDGE MA 02139 |
| Graham K Cooper |
director |
C/O RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121 |
| Kathleen E Walsh |
director |
C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001 |
| Arch Venture Fund Ix Overage, L.p. |
10 percent owner |
8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631 |
| Stephen C Knight |
director |
C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142 |
| Mark Fishman |
director |
C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
| Arch Venture Partners Ix, Llc |
10 percent owner |
8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
| Arch Venture Partners Ix, L.p. |
10 percent owner |
8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
| Arch Venture Partners Ix Overage, L.p. |
10 percent owner |
8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Beam Therapeutics (Beam Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BEAM has been successfully added to your